Comparing the new European cardiovascular disease prevention guideline with prior American heart association guidelines: An editorial review

Clinical Cardiology

Volumn 36, Issue 5, 2013, Pages

  Ton, Van Khue ^a   Martin, Seth S ^a   Blumenthal, Roger S ^a   Blaha, Michael J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLUENZA VACCINE; NEBIVOLOL; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

AGE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY CALCIUM SCORE; DISEASE CLASSIFICATION; DISEASE MARKER; ETHNICITY; EUROPE; FRAMINGHAM RISK SCORE; HUMAN; HYPERTENSION; INFLUENZA; INFLUENZA VACCINATION; LOW DRUG DOSE; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; REVIEW; RISK ASSESSMENT; UNITED STATES; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; PREVENTIVE HEALTH SERVICE; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84877766774     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22079     Document Type: Review

References (27)

1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952.
2. World Health Organization. Diet, nutrition and the prevention of chronic diseases; 2003. WHO Technical Report Series 916. http://whqlibdoc.who.int/trs/ who-trs-916.pdf.
3. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J. 2012; 33: 1635-1701.
4. Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008; 168: 1333-1339.
5. Erbel R, Mohlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis. The Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010; 56: 1397-1406.
6. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-2207.
7. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365: 2255-2267.
8. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J. 2007; 28: 2375-2414.
9. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Risk assessment tool for estimating your 10-year risk of having a heart attack. http://hp2010.nhlbihin.net/atpiii/ calculator.asp.
10. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. Circulation. 2010; 122: e584-e636.
11. Painter RC, de Rooij SR, Bossuyt PM, et al. Early onset of coronary artery disease after prenatal exposure to the Dutch famine. Am J Clin Nutr. 2006; 84: 322-327.
12. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002; 106: 3143-3421.
13. Sacco RL, Kargman DE, Gu Q, et al. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke. 1995; 26: 14-20.
14. Lackland DT, Elkind MSV, D'Agostino R, et al. Inclusion of stroke in cardiovascular risk prediction instruments. Stroke. 2012; 43: 1998-2027.
15. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011; 123: 1243-1262.
16. Kibos A, Guerchicoff A., Susceptibility genes for coronary heart disease and myocardial infarction. Acute Card Care. 2011; 13: 136-142.
17. Arbab-Zadeh A, Nakano M, Virmani R, et al. Acute coronary events. Circulation. 2012; 125: 1147-1156.
18. Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. J Am Coll Cardiol Img. 2009; 2: 675-688.
19. Blumenthal RS, Foody J, Wong ND., Preventive Cardiology: Companion to Braunwald's Heart Disease. New York, NY: Elsevier Health Sciences; 2011.
20. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005; 111: 499-510.
21. Shilinglaw B, Viera AJ, Edwards T, et al. Use of global coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of U.S. physicians. BMC Health Serv Res. 2012; 12: 20.
22. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary artery and other atherosclerotic vascular disease: 2011 update. J Am Coll Cardiol. 2011; 58: 2432-2446.
23. Blaha MJ, Blumenthal RS, Brinton EA, et al. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008; 2: 267-273.
24. Joshi PH, Chaudhari S, Blaha MJ, et al. A point-by-point response to recent arguments against the use of statins in primary prevention. Clin Cardiol. 2012; 35: 404-409.
25. Hayward RA, Krumholz HM, Zulman DM., Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010; 152: 69-77.
26. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002; 106: 388-391.
27. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.